|
6
| |
|
3
| |
3
| |
6
| |
|
|
| |
1
| |
|
3
| |
| |
|
2
| |
17
|
ADICET-ADI-001-BCELL
Phase I
OPEN TO ACCRUAL
|
ADP-0000-001-SCR
Phase N/A
OPEN TO ACCRUAL
|
ADP-0044-002-SPEARHEAD-1
Phase II
OPEN TO ACCRUAL
|
ADP-0055-001-MAGE-A4-SURPASS
Phase I
OPEN TO ACCRUAL
|
ALLOVIR-AVM-003-HC
Phase III
OPEN TO ACCRUAL *
|
ARCELLX-ACLX-001-DDBCMA
Phase I
OPEN TO ACCRUAL
|
CARSGEN-CT041-ST-02
Phase I
OPEN TO ACCRUAL *
|
CARSGEN-CT053-MM-02
Phase I/II
OPEN TO ACCRUAL
|
CELGENE-GC-LTFU-001
Phase N/A
OPEN TO ACCRUAL
|
FATE-FT576-101-MM
Phase I
OPEN TO ACCRUAL
|
GSK-3377794-LTFU
Phase N/A
OPEN TO ACCRUAL
|
IIT-SHAH-IL7-IL15-CD20-19
Phase I/II
OPEN TO ACCRUAL
|
INCYTE-INCB-39110-211-CRS
Phase II
OPEN TO ACCRUAL
|
JNJ-MY4002-CARTINUE-LTFU
Phase N/A
OPEN TO ACCRUAL
|
JUNO-017004-TRANSCEND-CLL
Phase I/II
OPEN TO ACCRUAL
|
LYELL-LYL-797-101
Phase I
OPEN TO ACCRUAL
|
SOTIO-BOXR1030
Phase I/II
OPEN TO ACCRUAL *
|
|
2
|
HOFFMANN-BO41932-TAPISTRY
Phase II
OPEN TO ACCRUAL
|
MERCK-MK1084-001
Phase I
OPEN TO ACCRUAL
|
|
2
|
HOFFMANN-BO41932-TAPISTRY
Phase II
OPEN TO ACCRUAL
|
MERCK-MK1084-001
Phase I
OPEN TO ACCRUAL
|
|
1
| |
|
|
1
| |
6
| |
|
|
1
|
|
| |
|
|
4
| |
|
2
|
3
| |
7
|
3
| |
5
| |
3
| |
|
|
1
| |
|
|
3
|
|
| |
| |
1
| |
|
3
|
| |
5
| |
|
1
| |
|
|
|
3
| |
6
| |
|
| |
|
2
| |
|
|
1
| |
2
|
| |
|
|
2
| |
1
|
2
| |
6
| |
|
3
| |
|
|
|
| |
2
| |
|
|
|
1
| |
|
10
|
3
|
1
| |
3
| |
|
7
|
6
| |
2
| |
|
| |
3
| |
4
|
| |
4
| |
|
4
| |
2
|
| |
2
| |
|
3
| |
6
| |
|
16
|
7
| |
1
|
1
| |
| |
|
12
|
4
|
| |
| |
1
| |
| |
| |
| |
2
| |
1
| |
| |
| |
| |
|
5
|
1
| |
1
| |
7
| |
5
| |
| |
| |
4
| |
3
| |
2
| |
1
| |
2
| |
|
|
7
| |
|
13
|
4
| |
6
| |
| |
12
| |
2
| |
|
7
|
3
| |
|
3
|
| |
|
|
2
| |
|
4
|
| |
8
| |
1
| |
|
|
| |
3
| |
|
2
| |
|
1
| |
1
| |
1
|
IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
|
|
7
|
ADP-0000-001-SCR
Phase N/A
OPEN TO ACCRUAL
|
ALLIANCE-A151804
Phase N/A
OPEN TO ACCRUAL
|
ALLIANCE-A222004-ANOREXIA
Phase III
OPEN TO ACCRUAL
|
ALLOVIR-AVM-003-HC
Phase III
OPEN TO ACCRUAL *
|
CTN-1705
Phase III
OPEN TO ACCRUAL
|
IIT-RUNAAS-TILDRAKIZUMAB-AGVHD
Phase II
OPEN TO ACCRUAL
|
INCYTE-INCB-39110-211-CRS
Phase II
OPEN TO ACCRUAL
|
|